Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

[1]  M. Miravitlles,et al.  Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis , 2017, Respiratory Research.

[2]  J. Riley,et al.  Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study , 2017, Advances in Therapy.

[3]  A. Huerta,et al.  Cost-Effectiveness Analysis Of Two Long-Acting Muscarinic Antagonists For Copd Treatment In Spain: Umeclidinium VS. Tiotropium (HO-17-18472) , 2017 .

[4]  I. Oyagüez,et al.  Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain , 2017 .

[5]  A. Ismaila,et al.  A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD , 2017, Pulmonary Therapy.

[6]  M. Miravitlles,et al.  Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study , 2017, International journal of chronic obstructive pulmonary disease.

[7]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease , 2017 .

[8]  Pere Almagro,et al.  Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable , 2017 .

[9]  A. Ismaila,et al.  Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  A. Briggs,et al.  Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  A. Ismaila,et al.  Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  M. Roset,et al.  Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study , 2017, International journal of chronic obstructive pulmonary disease.

[13]  R. Stanford,et al.  Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model , 2017, International journal of chronic obstructive pulmonary disease.

[14]  Reiner Leidl,et al.  External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  E. Kerwin,et al.  Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study , 2017, International journal of chronic obstructive pulmonary disease.

[16]  E. Ota,et al.  Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). , 2017, The Cochrane database of systematic reviews.

[17]  J. Soriano,et al.  Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study , 2017, International journal of chronic obstructive pulmonary disease.

[18]  H. Chrystyn,et al.  A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices , 2016, npj Primary Care Respiratory Medicine.

[19]  A. Tebboth,et al.  UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD , 2016, ClinicoEconomics and outcomes research : CEOR.

[20]  H. Chrystyn,et al.  The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries , 2016, BMC Health Services Research.

[21]  A. Church,et al.  A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[22]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[23]  F. Maltais,et al.  A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[24]  C. Micheletto,et al.  Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues , 2016, International journal of chronic obstructive pulmonary disease.

[25]  Dave Singh,et al.  Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. , 2016, Respiratory medicine.

[26]  M. Miravitlles,et al.  Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients , 2016, International journal of chronic obstructive pulmonary disease.

[27]  Dave Singh,et al.  Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial , 2015, BMC Pulmonary Medicine.

[28]  A. Church,et al.  Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. , 2015, Respiratory medicine.

[29]  Sally J. Singh,et al.  Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials , 2014, Therapeutic advances in respiratory disease.

[30]  N. Richard,et al.  Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. , 2014, Respiratory medicine.

[31]  A. Ismaila,et al.  Validating A Model To Predict Disease Progression Outcomes In Patients With COPD. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  M. Miravitlles,et al.  Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems , 2014, Health and Quality of Life Outcomes.

[33]  P. Poole,et al.  Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[34]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[35]  Ciro Casanova,et al.  Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study , 2014, PloS one.

[36]  A. Church,et al.  Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.

[37]  D. Tashkin,et al.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.

[38]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[39]  M. R. Rutten-van Mölken,et al.  Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease , 2012, PharmacoEconomics.

[40]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD , 2012 .

[41]  Mario Cazzola,et al.  Pharmacology and Therapeutics of Bronchodilators , 2012, Pharmacological Reviews.

[42]  M. Miravitlles,et al.  Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable , 2012 .

[43]  A. Briggs,et al.  Predicting EQ-5D values using the SGRQ. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  J. Soriano,et al.  [Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. , 2010, Archivos de bronconeumologia.

[45]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[46]  Anna García-Altés,et al.  Spanish recommendations on economic evaluation of health technologies , 2010, The European Journal of Health Economics.

[47]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[48]  J. Soriano,et al.  Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.

[49]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[50]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[51]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[52]  M. Miravitlles,et al.  Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional , 2004 .

[53]  M. Miravitlles,et al.  [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]. , 2004, Archivos de bronconeumologia.

[54]  C. Cooper,et al.  The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.

[55]  Ramon Gisbert,et al.  Costs of chronic bronchitis and COPD: a 1-year follow-up study. , 2003, Chest.

[56]  P Stein,et al.  The Consumer Price Index (CPI). , 1992, Trends & techniques in the contemporary dental laboratory.